{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:10:51Z","timestamp":1769605851411,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004781","name":"Institut Pengurusan dan Pemantauan Penyelidikan, Universiti Malaya","doi-asserted-by":"publisher","award":["PG057-2015A"],"award-info":[{"award-number":["PG057-2015A"]}],"id":[{"id":"10.13039\/501100004781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00520-019-05133-0","type":"journal-article","created":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T00:02:01Z","timestamp":1573948921000},"page":"3237-3247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-3072","authenticated-orcid":false,"given":"Bee Kim","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siew Siang","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Chia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian Meng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmini","family":"Balashanker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping Chong","family":"Bee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,16]]},"reference":[{"issue":"1","key":"5133_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","volume":"63","author":"PJ Fialkow","year":"1977","unstructured":"Fialkow PJ, Jacobson RJ, Papayannopoulou T (1977) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage. Am J Med 63(1):125\u2013130","journal-title":"Am J Med"},{"issue":"1","key":"5133_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholom\u00e4us A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, M\u00fcller MC, Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung and the German CML Study Group (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 126(1):42\u201349","journal-title":"Blood."},{"issue":"8","key":"5133_CR3","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Saussele","year":"2016","unstructured":"Saussele S, Richter J, Hochhaus A, Mahon FX (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 30(8):1638\u20131647","journal-title":"Leukemia."},{"issue":"22","key":"5133_CR4","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1182\/blood.V128.22.3610.3610","volume":"128","author":"Z Alrabiah","year":"2016","unstructured":"Alrabiah Z, Alhossan A, Yun S, MacDonald K, Abraham I (2016) Adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia: meta-analyses of prevalence rates by measurement method. Blood 128(22):3610","journal-title":"Blood"},{"issue":"14","key":"5133_CR5","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 117(14):3733\u20133736","journal-title":"Blood."},{"issue":"14","key":"5133_CR6","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381\u20132388","journal-title":"J Clin Oncol"},{"key":"5133_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4137\/CMO.S32822","volume":"10","author":"NI Al-Dewik","year":"2016","unstructured":"Al-Dewik NI, Morsi HM, Samara MM, Ghasoub RS, Gnanam CC, Bhaskaran SK et al (2016) Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar? Clin Med Insights Oncol 10:95\u2013104","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"5133_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11096-013-9876-7","volume":"36","author":"TC Chen","year":"2014","unstructured":"Chen TC, Chen LC, Huang YB, Chang CS (2014) Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int J Clin Pharm 36(1):172\u2013181","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"5133_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ajh.22019","volume":"86","author":"P Ganesan","year":"2011","unstructured":"Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, Nandennavar M (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86(6):471\u2013474","journal-title":"Am J Hematol"},{"issue":"6","key":"5133_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics. 25(6):481\u2013496","journal-title":"PharmacoEconomics."},{"issue":"2","key":"5133_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H (2016) Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91(2):252\u2013265","journal-title":"Am J Hematol"},{"issue":"3","key":"5133_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000362816","volume":"87","author":"D Cella","year":"2014","unstructured":"Cella D, Nowinski CJ, Frankfurt O (2014) The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology. 87(3):133\u2013147","journal-title":"Oncology."},{"key":"5133_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1477-7525-11-167","volume":"11","author":"I Hirji","year":"2013","unstructured":"Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient\u2019s perspective. Health Qual Life Outcomes 11:167","journal-title":"Health Qual Life Outcomes"},{"key":"5133_CR14","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2147\/PPA.S92125","volume":"9","author":"M Kekale","year":"2015","unstructured":"Kekale M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adher 9:1733\u20131740","journal-title":"Patient Prefer Adher"},{"issue":"6","key":"5133_CR15","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00520-014-2229-9","volume":"22","author":"A Chan","year":"2014","unstructured":"Chan A, Lees J, Keefe D (2014) The changing paradigm for supportive care in cancer patients. Support Care Cancer 22(6):1441\u20131445","journal-title":"Support Care Cancer"},{"issue":"9","key":"5133_CR16","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1111\/jan.12978","volume":"72","author":"M Kekale","year":"2016","unstructured":"Kekale M, Soderlund T, Koskenvesa P, Talvensaari K, Airaksinen M (2016) Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study. J Adv Nurs 72(9):2196\u20132206","journal-title":"J Adv Nurs"},{"issue":"11","key":"5133_CR17","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/j.clml.2018.06.026","volume":"18","author":"A Leader","year":"2018","unstructured":"Leader A, Benyamini N, Gafter-Gvili A, Dreyer J, Calvarysky B, Amitai A et al (2018) Effect of adherence-enhancing interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): a quasi-experimental pre-post intervention multicenter pilot study. Clin Lymphoma Myeloma Leuk 18(11):e449\u2013ee61","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"5133_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00520-016-3486-6","volume":"25","author":"SM Moulin","year":"2017","unstructured":"Moulin SM, Eutropio FJ, Souza JO, Busato FO, Olivieri DN, Tadokoro CE (2017) The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Support Care Cancer 25(3):951\u2013955","journal-title":"Support Care Cancer"},{"issue":"2","key":"5133_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12032-011-9926-8","volume":"29","author":"JH Moon","year":"2012","unstructured":"Moon JH, Sohn SK, Kim SN, Park SY, Yoon SS, Kim IH, Kim HJ, Kim YK, Min YH, Cheong JW, Kim JS, Jung CW, Kim DH (2012) Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol 29(2):1179\u20131185","journal-title":"Med Oncol"},{"issue":"6","key":"5133_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/1078155215608523","volume":"22","author":"MS Lam","year":"2016","unstructured":"Lam MS, Cheung N (2016) Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract 22(6):741\u2013748","journal-title":"J Oncol Pharm Pract"},{"key":"5133_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2147\/PPA.S132894","volume":"11","author":"BK Tan","year":"2017","unstructured":"Tan BK, Tan SB, Chen LC, Chang KM, Chua SS, Balashanker S, Kamarul Jaman HNB, Edmund SC, Bee PC (2017) Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study. Patient Prefer Adher 11:1027\u20131034","journal-title":"Patient Prefer Adher"},{"issue":"3","key":"5133_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000251","volume":"7","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7(3):e1000251","journal-title":"PLoS Med"},{"issue":"6","key":"5133_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u00dfele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 122(6):872\u2013884","journal-title":"Blood."},{"issue":"9","key":"5133_CR24","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo D, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H (2018) Chronic myeloid leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 16(9):1108\u20131135","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"5133_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23(3):825\u2013836","journal-title":"Qual Life Res"},{"issue":"2","key":"5133_CR26","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.1188\/14.CJON.E12-E18","volume":"18","author":"M Coleman","year":"2014","unstructured":"Coleman M (2014) Patient empowerment in the management of chronic myeloid leukemia. Clin J Oncol Nurs 18(2):E12\u2013E18","journal-title":"Clin J Oncol Nurs"},{"issue":"6","key":"5133_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 23(6):1054\u20131061","journal-title":"Leukemia."},{"issue":"1","key":"5133_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood. 128(1):17\u201323","journal-title":"Blood."},{"key":"5133_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","volume":"6","author":"S Michie","year":"2011","unstructured":"Michie S, van Stralen MM, West R (2011) The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 6:42","journal-title":"Implement Sci"},{"issue":"6","key":"5133_CR30","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s10147-015-0843-2","volume":"20","author":"K Hosoya","year":"2015","unstructured":"Hosoya K, Mochinaga S, Emoto A, Yokoo H, Tokushima H, Egoshi M, Sueoka-Aragane N, Kimura S (2015) Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia. Int J Clin Oncol 20(6):1203\u20131210","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"5133_CR31","first-page":"411","volume":"21","author":"D Gomez-Almaguer","year":"2016","unstructured":"Gomez-Almaguer D, Saldana-Vazquez R, Tarin-Arzaga L, Herrera-Rojas MA, Vazquez-Mellado de Larracoechea A, Cantu-Rodriguez OG et al (2016) Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure. Hematology (Amsterdam, Netherlands) 21(7):411\u2013414","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"5133_CR32","doi-asserted-by":"publisher","first-page":"a1655","DOI":"10.1136\/bmj.a1655","volume":"337","author":"P Craig","year":"2008","unstructured":"Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M et al (2008) Developing and evaluating complex interventions: the new Medical Research Council guidance. Bmj. 337:a1655","journal-title":"Bmj."}],"updated-by":[{"DOI":"10.1007\/s00520-019-05212-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000}}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05133-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05133-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05133-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:23:08Z","timestamp":1605399788000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05133-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,16]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["5133"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05133-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00520-019-05212-2","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,16]]},"assertion":[{"value":"18 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Revised Funding Information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approvals for this study was obtained from the Medical Research and Ethics Committee (MREC) Ministry of Health Malaysia (Ref. No. NMRR-14-1466-23315 [IIR] dated 7 September 2015) and Medical Ethics Committee of University Malaya Medical Centre (Ref. No. 201411-802 dated 2 November 2014).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}